Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
MIAMI, FLORIDA - Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a micro-cap biotech company valued at $74.7 million, has released preclinical data suggesting that its drug candidate, Telomir-1, may reverse signs of cellular aging. The stock, currently trading near its 52-week low of $2.51, down 60% over the past year, reflects the speculative nature of early-stage pharmaceutical companies. The in vitro studies, conducted in partnership with SmartAssays, indicate improved cell functions that are commonly affected by aging and stress, such as mitochondrial activity and oxidative stress.
The research, which has not yet involved human trials, points to Telomir-1’s potential in improving cell viability, boosting energy production within cells, reducing oxidative damage, and protecting cells from metal-induced toxicity. These findings are particularly relevant as they provide a mechanistic basis for Telomir’s research into autism spectrum disorder (ASD) and spasmodic dysphonia (SD), conditions marked by similar cellular disruptions. According to InvestingPro analysis, the company currently operates with moderate debt levels and faces profitability challenges, with a loss of $0.56 per share in the last twelve months.
ASD affects 1 in 36 children in the United States, and while treatments are available for behavioral symptoms, none target the underlying cellular biology. Telomir-1 aims to address this gap. SD, affecting approximately 50,000 Americans, is currently managed with botulinum toxin injections, which offer temporary relief. Telomir-1’s potential effects on oxidative stress and neurodegeneration could present new avenues for treatment.
In light of these developments, Telomir plans to engage with the FDA’s Rare Disease Endpoint Advancement (RDEA) Pilot Program to advance the development of Telomir-1, particularly for rare diseases such as Progeria and Wilson’s disease.
Telomir Pharmaceuticals is a pre-clinical stage company focusing on age-reversal science, with a goal to develop treatments that not only extend lifespan but also improve the quality of life. The company emphasizes that Telomir-1 is still in the preclinical phase and has not been tested in humans, with no guarantee of FDA approval for marketing.
This information is based on a press release statement from Telomir Pharmaceuticals, Inc. and contains forward-looking statements subject to risks and uncertainties. Telomir encourages investors to review additional details in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. With the next earnings report scheduled for May 28, 2025, investors seeking deeper insights can access additional financial metrics and 7 more exclusive ProTips through InvestingPro, including detailed analysis of the company’s valuation and growth prospects.
In other recent news, Telomir Pharmaceuticals has announced significant preclinical results for its investigational drug, Telomir-1, in prostate cancer studies. The drug demonstrated a 50% reduction in tumor growth in animal models, using aggressive human prostate cancer cells. Additionally, Telomir-1 appeared to mitigate the toxic side effects of Paclitaxel, a common chemotherapy drug, by preventing fatalities in animal models treated with a combination of low-dose Telomir-1 and Paclitaxel. Telomir Pharmaceuticals also revealed that Telomir-1 could reverse cellular aging processes by restoring calcium balance and reducing oxidative stress, potentially offering a novel treatment for age-related diseases. Further, the company reported a breakthrough in stabilizing reactive forms of silver for medical applications, suggesting potential for new antimicrobial treatments. Telomir is advancing Telomir-1 towards clinical development for various conditions, including cancer and age-related diseases. The company’s CEO, Erez Aminov, and Chief Scientific Advisor, Dr. Angel, have emphasized the drug’s potential in transforming treatment approaches. As Telomir-1 is still in the preclinical phase, ongoing research will determine its safety and efficacy in humans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.